Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

577 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.
Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, Yamakado K, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T; Liver Cancer Study Group of Japan. Kudo M, et al. Among authors: hiraoka a. Oncology. 2014;87 Suppl 1:22-31. doi: 10.1159/000368142. Epub 2014 Nov 22. Oncology. 2014. PMID: 25427730 Review.
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.
Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan. Kudo M, et al. Among authors: hiraoka a. Liver Cancer. 2014 Oct;3(3-4):458-68. doi: 10.1159/000343875. Liver Cancer. 2014. PMID: 26280007 Free PMC article. Review.
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.
Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Kawasaki H, Hiasa Y, Michitaka K; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Hiraoka A, et al. Liver Cancer. 2017 Jun;6(3):204-215. doi: 10.1159/000452846. Epub 2017 Mar 9. Liver Cancer. 2017. PMID: 28626732 Free PMC article.
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, Joko K, Shimada N, Deguchi A, Ishikawa T, Imai M, Tsuji K, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Hiraoka A, et al. Dig Dis. 2017;35(6):602-610. doi: 10.1159/000480256. Epub 2017 Oct 17. Dig Dis. 2017. PMID: 29040999 Clinical Trial.
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.
Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M. Hiraoka A, et al. Liver Cancer. 2017 Nov;6(4):325-336. doi: 10.1159/000479984. Epub 2017 Sep 22. Liver Cancer. 2017. PMID: 29234636 Free PMC article.
Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H, Hiraoka A, Ishimaru Y, Murakami T, Kitahata S, Ueki H, Aibiki T, Okudaira T, Miyamoto Y, Yamago H, Iwasaki R, Tomida H, Mori K, Kishida M, Tsubouchi E, Miyata H, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Michitaka K, Kudo M. Izumoto H, et al. Among authors: hiraoka a. Oncology. 2017;93 Suppl 1:120-126. doi: 10.1159/000481242. Epub 2017 Dec 20. Oncology. 2017. PMID: 29258105 Free article.
Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma.
Kariyama K, Nouso K, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Wakuta A, Oonishi A, Kumada T, Kudo M, Group OBOTRPEFHRS, Group H. Kariyama K, et al. Among authors: hiraoka a. Cancers (Basel). 2019 Feb 10;11(2):203. doi: 10.3390/cancers11020203. Cancers (Basel). 2019. PMID: 30744175 Free PMC article.
Combination of Resection and Ablative Treatment for Hepatocellular Carcinoma: Usefulness of Complementary Radiofrequency Ablation.
Hiraoka A, Hirooka M, Ochi H, Koizumi Y, Izumoto H, Ueki H, Tsuruta M, Ono A, Yoshino T, Aibiki T, Okudaira T, Yamago H, Suga Y, Iwasaki R, Mori K, Miyata H, Kishida M, Tsubouchi E, Abe M, Matsuura B, Ninomiya T, Joko K, Kawasaki H, Hiasa Y, Michitaka K. Hiraoka A, et al. Oncology. 2019;96(5):242-251. doi: 10.1159/000496225. Epub 2019 Mar 20. Oncology. 2019. PMID: 30893698
577 results